UROV News and Press, Urovant Sciences Ltd. From 10/11/19

Biotech is in the doldrums. The SPDR S&P Biotech ETF  declined 18% in the past six months, and money continues to flow out of the sector. While several biotechs managed to IPO in September and October , it's not all roses. ADC Therapeutics pulled its plans to list citing market...

Vibegron further improved treatment benefit on key overactive bladder (OAB) symptoms over the 40-week extension period 41% of patients on vibegron became “dry,” defined as having no urge urinary incontinence episodes at week 52 Vibegron demonstrated a favorable l...

Sumitomo Dainippon Pharma is expected to fully assume Roivant’s ownership interest of Urovant Sciences (approximately 75% of outstanding Urovant shares); definitive agreement expected by the end of October 2019 Sumitomo Dainippon Pharma is a top-ten Japanese listed multi-nationa...

Urovant Sciences Ltd. (UROV) Q1 2019 Results Earnings Conference Call August 13, 2019, 04:30 PM ET Company Participants Christine Ocampo - Senior Vice President and Chief Accounting Officer Keith Katkin - Chief Executive Officer Cornelia Haag-Molkenteller - Chief Medical Officer ...

Urovant Sciences (NASDAQ: UROV ): Q1 GAAP EPS of -$0.94 beats by $0.02 . More news on: Urovant Sciences Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the 2019 first fiscal quarter ended June 30, 2019. Recent Business Highlights ...

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will report 2019 first fiscal quarter financial results after the close of U.S. financial markets on Tuesday...

The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) took a steep hit last week, crashing from 3,422.32 points on Monday’s (July 8) open to 3,315.46 points as of 1:32 p.m. EDT on Friday (July 12). A likely catalyst for the index’s crash was US President Donald Trump’s pled...

Urovant Sciences Limited (UROV) Q4 2018 Earnings Conference Call June 13, 2019 04:30 PM ET Company Participants Christine Ocampo - Senior Vice President and Chief Accounting Officer Keith Katkin - Chief Executive Officer Cornelia Haag-Molkenteller - Chief Medical Officer Michae...

Urovant Sciences (NASDAQ: UROV ): Q4 GAAP EPS of -$0.96 misses by $0.01 . More news on: Urovant Sciences Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...